Drug-related Deaths

Anneliese Dodds Excerpts

Wednesday 5th November 2025 Commons Chamber

[Charlotte Nichols]

I absolutely agree. Later, I will try to develop my argument for that kind of approach, which we could take here but do not.

As a Parliament and as a society, we may have inadvertently come to accept the yearly statistics, and have perhaps not given them the necessary thought, but I stress that there are cost-effective solutions that could save the taxpayer money and save the lives of our constituents, while taking money out of the pockets of exploitative, organised criminal gangs.

I am afraid to say that the problem may be far worse than is recognised. A recent report by King’s College London indicates that there has been a severe under-reporting of drug-related deaths over the past 15 years. The researchers found that drug-related deaths have been under-reported by 30%, and opioid-related deaths between 2011 and 2022 were found to be 55% higher than recorded, putting the estimated number of opioid-related deaths in that period north of 39,000.

[Anneliese Dodds (Oxford East) (Lab/Co-op)]

I am grateful to my hon. Friend for securing this debate. She will be aware that many of those who have died from complications and overdoses related to opioids died on their own. That reflects the social isolation that so many experience when they become addicted to drugs. Does she agree that it is incredibly important that the social isolation of those seeking to move beyond addiction is broken through, and will she join me in thanking organisations like Jungle in my constituency, which seek to provide companionship and support for those who are trying to move beyond addiction?

[Charlotte Nichols]

My right hon. Friend is exactly right. The clearest way to recovery is with companionship and support—there is no path to recovery without that—and I of course give credit to the organisation she mentioned that is doing such fantastic work in this space, as we were discussing earlier today.

The implications of the under-reporting of drug-related deaths are that the problem is far worse than previously thought and the decision to cut funding to services under the previous Government was based on flawed figures. The National Audit Office reported that between 2014 and 2022 there was a 40% reduction in real-terms spending on adult drug and alcohol services, so I do not think it is a coincidence that the Office for National Statistics has reported a near doubling in drug-related deaths since 2014, and that the number of deaths only rises every year.

It is clear that the problem has been made substantively worse by under-investment by the previous Government. We can all acknowledge that, but acknowledgment without reform is meaningless. Persisting with failed, punitive policies will only deepen a crisis that already ranks among Europe’s worst. Now is the time to show the difference a Labour Government can make by putting in place harm-reduction policies that will start to undo this extensive damage.

As I mentioned previously, and I will repeat again because it is important, near half of all drug-related deaths registered in 2024 were confirmed to involve an opioid. In addition, this year’s ONS report found that the number of deaths involving nitazenes—a group of highly potent synthetic opioids—almost quadrupled from the year before. This marks the beginning of a new stage in the drug-related deaths crisis. As we have seen across the Atlantic, once those synthetic opioids take hold, it becomes all the more difficult to limit their devastation.

I welcome this Government’s changes to the human medicines regulation that further expanded access to naloxone, the lifesaving opioid antidote administered in the event of an overdose. Indeed, naloxone plays a vital role in the fight against drug-related deaths. However, further change is necessary and naloxone should be available rapidly and reliably in every community pharmacy in the UK, so that it can be quickly accessed in the event of an overdose.

It is important to note that naloxone cannot be administered by the person overdosing and must instead be administered by someone else. That necessitates further education on the existence of naloxone, and how and when to use it, with people who may come into contact with people who use opioids, including frontline service workers, such as police officers and transport workers, and the loved ones of those struggling with addiction.

The period immediately after release from prison or discharge from hospital is when risk peaks. Opt-out pathways for naloxone distribution should be the norm. Take-home naloxone on release or discharge, same-day linkage to community treatment and a clear pathway for handover care are essential for people struggling with substance use disorders.

As of December 2021, the Government estimated the annual cost of illegal drug use in England to be £20 billion. Around 48% of that was attributed to drug-related crime, while harms linked to drug-related deaths and homicide accounted for a further 33%. Notably, the majority of those costs are associated with the estimated 300,000 people who use opiates and crack cocaine in England.

Dame Carol Black’s landmark 2021 review of UK drug policy found that for every for every £1 spent on treatment, £4 are saved through reduced demand on the health and justice systems. In the face of rising fatalities and a cost of living crisis, failing to scale treatment and harm-reduction measures is both morally indefensible and financially illiterate. If we want to realise that four-to-one return, we must provide long-term funding for organisations delivering services. Drug treatment services can only deliver if they are able to retain staff, train consistently and scale according to demand.